

Nina Kimer

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/4697086/publications.pdf>

Version: 2024-02-01

45
papers

744
citations

687363
13
h-index

552781
26
g-index

47
all docs

47
docs citations

47
times ranked

1105
citing authors

#	ARTICLE	IF	CITATIONS
1	Systematic review with meta-analysis: the effects of rifaximin in hepatic encephalopathy. <i>Alimentary Pharmacology and Therapeutics</i> , 2014, 40, 123-132.	3.7	168
2	Meta-analysis: the safety and efficacy of vaptans (tolvaptan, satavaptan and lixivaptan) in cirrhosis with ascites or hyponatraemia. <i>Alimentary Pharmacology and Therapeutics</i> , 2012, 36, 619-626.	3.7	73
3	The continuous reaction times method for diagnosing, grading, and monitoring minimal/covert hepatic encephalopathy. <i>Metabolic Brain Disease</i> , 2013, 28, 231-234.	2.9	61
4	Rifaximin has no effect on hemodynamics in decompensated cirrhosis: A randomized, double-blind, placebo-controlled trial. <i>Hepatology</i> , 2017, 65, 592-603.	7.3	60
5	Rifaximin has minor effects on bacterial composition, inflammation, and bacterial translocation in cirrhosis: A randomized trial. <i>Journal of Gastroenterology and Hepatology (Australia)</i> , 2018, 33, 307-314.	2.8	51
6	Differential inflammasome activation predisposes to acute-on-chronic liver failure in human and experimental cirrhosis with and without previous decompensation. <i>Gut</i> , 2021, 70, gutjnl-2019-320170.	12.1	47
7	Cardiodynamic state is associated with systemic inflammation and fatal acute-on-chronic liver failure. <i>Liver International</i> , 2020, 40, 1457-1466.	3.9	46
8	Beta-blockers in cirrhosis and refractory ascites: a retrospective cohort study and review of the literature. <i>Scandinavian Journal of Gastroenterology</i> , 2015, 50, 129-137.	1.5	34
9	Antiviral therapy for prevention of hepatocellular carcinoma in chronic hepatitis C: systematic review and meta-analysis of randomised controlled trials. <i>BMJ Open</i> , 2012, 2, e001313.	1.9	29
10	Fecal microbiota transplantation in hepatic encephalopathy: a systematic review. <i>Scandinavian Journal of Gastroenterology</i> , 2021, 56, 560-569.	1.5	26
11	New vasoactive peptides in cirrhosis: organ extraction and relation to the vasodilatory state. <i>European Journal of Clinical Investigation</i> , 2014, 44, 441-452.	3.4	24
12	Cameron lesions: an often overlooked cause of iron deficiency anaemia in patients with large hiatal hernias. <i>BMJ Case Reports</i> , 2010, 2010, bcr0620103129-bcr0620103129.	0.5	16
13	Safety, efficacy, and patient acceptability of rifaximin for hepatic encephalopathy. <i>Patient Preference and Adherence</i> , 2014, 8, 331.	1.8	16
14	The impact of rifaximin on inflammation and metabolism in alcoholic hepatitis: A randomized clinical trial. <i>PLoS ONE</i> , 2022, 17, e0264278.	2.5	14
15	Atorvastatin for prevention of disease progression and hospitalisation in liver cirrhosis: protocol for a randomised, double-blind, placebo-controlled trial. <i>BMJ Open</i> , 2020, 10, e035284.	1.9	8
16	Prognosis of patients with ascites after PleurX insertion: an observational study. <i>Scandinavian Journal of Gastroenterology</i> , 2018, 53, 340-344.	1.5	7
17	The Psychometric Hepatic Encephalopathy Syndrome score does not correlate with blood ammonia, endotoxins or markers of inflammation in patients with cirrhosis. <i>Translational Gastroenterology and Hepatology</i> , 2021, 6, 8-8.	3.0	7
18	No effect of rifaximin on soluble CD163, mannose receptor or type III and IV neopeptide collagen markers in decompensated cirrhosis: Results from a randomized, placebo controlled trial. <i>PLoS ONE</i> , 2018, 13, e0203200.	2.5	6

#	ARTICLE	IF	CITATIONS
19	Pathophysiological-based treatments of complications of cirrhosis. Scandinavian Journal of Gastroenterology, 2020, 55, 383-394.	1.5	6
20	Rifaximin for people with hepatic encephalopathy. The Cochrane Library, 0, , .	2.8	5
21	Low ascitic fluid total protein levels is not associated to the development of spontaneous bacterial peritonitis in a cohort of 274 patients with cirrhosis. Scandinavian Journal of Gastroenterology, 2018, 53, 200-205.	1.5	5
22	Tunneled Peritoneal Catheter for Refractory Ascites in Cirrhosis: A Randomized Case-Series. Medicina (Lithuania), 2020, 56, 565.	2.0	4
23	Nonalcoholic Fatty Liver Disease and Cardiovascular Disease: Overlapping Mechanisms. Seminars in Liver Disease, 2021, 41, 235-247.	3.6	4
24	Patients With Cirrhosis Have Elevated Bone Turnover but Normal Hepatic Production of Osteoprotegerin. Journal of Clinical Endocrinology and Metabolism, 2022, 107, e980-e995.	3.6	4
25	The royal free hospital cirrhosis glomerular filtration rate: Validation in a danish cohort. Hepatology, 2017, 66, 1360-1361.	7.3	3
26	A Danish population-based case series of patients with liver cirrhosis and coronavirus disease 2019. Scandinavian Journal of Gastroenterology, 2021, 56, 453-457.	1.5	3
27	Development and predictive validity of the cirrhosis-associated ascites symptom scale: A cohort study of 103 patients. World Journal of Gastroenterology, 2018, 24, 1650-1657.	3.3	3
28	Research update for articles published in <scp>EJCI</scp> in 2014. European Journal of Clinical Investigation, 2016, 46, 880-894.	3.4	2
29	Advances in the treatment of portal hypertension in cirrhosis. Expert Review of Gastroenterology and Hepatology, 2016, 10, 1-9.	3.0	2
30	Rifaximin for the Prevention and Treatment of Hepatic Encephalopathy: A Systematic Review With Meta-Analyses of Randomised Controlled Trials. Journal of Clinical and Experimental Hepatology, 2017, 7, S78-S79.	0.9	2
31	Indications and methods for measuring portal hypertension in cirrhosis. Scandinavian Journal of Gastroenterology, 2022, 57, 1149-1157.	1.5	2
32	Letter: the effects of rifaximin in hepatic encephalopathy - authors' reply. Alimentary Pharmacology and Therapeutics, 2014, 40, 858-859.	3.7	1
33	P1337 : Randomized trial with rifaximin in liver cirrhosis. Effects on the haemodynamic and inflammatory state. Journal of Hepatology, 2015, 62, S858.	3.7	1
34	Beta-blockers alone or in combination with isosorbide mononitrate for secondary prevention of bleeding from gastro-esophageal varices in adults with cirrhosis and gastro-oesophageal varices. The Cochrane Library, 0, , .	2.8	1
35	Editorial: non-“selective beta blockers” in and out of circulation. Alimentary Pharmacology and Therapeutics, 2021, 53, 632-633.	3.7	1
36	Editorial: timing of carvedilol “promoting survivors in cirrhosis. Alimentary Pharmacology and Therapeutics, 2022, 56, 172-173.	3.7	1

#	ARTICLE	IF	CITATIONS
37	Outcomes of COVID-19 among Patients with Chronic Liver Disease: A Danish Prospective, Population-Based Cohort Study. GastroHep, 2022, 2022, 1-10.	0.6	1
38	Letter: vaptans for the treatment of hyponatraemia and ascites in patients with cirrhosis – authors’ reply. Alimentary Pharmacology and Therapeutics, 2012, 36, 1104-1104.	3.7	0
39	584 NEW VASCULAR BIOMARKERS IN CIRRHOSIS: ORGAN EXTRACTION AND RELATION TO THE VASODILATORY STATE. Journal of Hepatology, 2013, 58, S239.	3.7	0
40	206 RIFAXIMIN IN THE TREATMENT AND PROPHYLAXIS OF HEPATIC ENCEPHALOPATHY IN CHRONIC LIVER DISEASE: A META-ANALYSIS. Journal of Hepatology, 2013, 58, S90.	3.7	0
41	Beta-blockers alone or with isosorbide mononitrate for primary prevention in adults with cirrhosis and gastro-oesophageal varices. The Cochrane Library, 0, , .	2.8	0
42	PTU-094 – The Assessment of Resting Energy Expenditure in Patients with Cirrhosis Remains Problematic. Gut, 2016, 65, A101.1-A101.	12.1	0
43	The PHES Score Does Not Correlate With Blood Ammonia Levels, Circulating Endotoxins or Markers of Systemic Inflammation. Journal of Clinical and Experimental Hepatology, 2017, 7, S35-S36.	0.9	0
44	Nurse assisted follow-up after admission with decompensation in cirrhosis: a systematic review and meta-analysis. Journal of Hepatology, 2020, 73, S563-S564.	3.7	0
45	Tunnelled peritoneal catheter versus large volume paracentesis for refractory ascites in cirrhosis: a randomized controlled trial. Journal of Hepatology, 2020, 73, S749-S750.	3.7	0